Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial

JAMA

Volumn 299, Issue 3, 2008, Pages 289-295

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b   Renshaw, Andrew A ^a   Loffredo, Marian ^a   Kantoff, Philip W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUTAMIDE; GONADORELIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; FOLLOW UP; HAZARD RATIO; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNITED STATES; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CAUSE OF DEATH; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL;

EID: 38349164176     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.3.289     Document Type: Article

References (28)

1. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243-1252.
2. Shipley WU, Lu JD, Pilepich MV, et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys. 2002;54(5):1302-1310.
3. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Tran-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6(11):841-850.
4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression therapy and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360(9327):103-108.
5. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292 (7):821-827.
6. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420-2425.
7. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456.
8. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clin Oncol. 2006;24(24):3979-3983.
9. Beahrs OH, Henson DE, Hutler RVP. American Joint Committee on Cancer: Manual for Staging Cancer. 4th ed. Philadelphia, PA: JP Lippincott; 1992.
10. Oken MM, Creech RH, Torrey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
11. Johnston AS, Piccirillo JF, Creech C, Littenberg B, Jeffe D, Spitznagel EL. Validation of a comorbidity education program. J Registry Mgt. 2001;28:125-131.
12. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Mgt. 2003;30:8-14.
13. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291 (20):2441-2447.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
16. Elixhauser A, Steiner C, Harris R, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
17. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337(5):295-300.
18. Agresti A, ed. An Introduction to Categorical Data Analysis. 2nd ed. New York, NY: John Wiley & Sons; 2002:16-52.
19. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-500.
20. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141-1154.
22. Neter J, Wassermann W, Kutner M, eds. Simultaneous inferences and other topics in regression analyses-1. In: Applied Linear Regression Models. Homewood, IL: Richard D Irwin; 1983:150-153.
23. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer; 2003:243-293.
24. Klein JP, Moeschberger ML. Refinements of the semiparametric proportional hazards model. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer; 2003:295-328.
25. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
26. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
27. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576-3581.
28. Walz J, Gallina A, Hutterer G, et al. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69(1):88-94.